Alys Pharmaceuticals announces CTA submission for ALY-301, the first mast cell selective c-Kit inhibitor for treatment of Cold Urticaria

/in

ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]

Read more

AMSilk enters Consumer Care Market with the launch of AMSilk4Shine and AMSilk4Care

/in

Neuried, Germany, 10 June 2025 – AMSilk, a global leader in advanced biomaterials based on silk proteins, today announces its expansion into the consumer care market with the launch of AMSilk4Shine and AMSilk4Care. AMSilk4Shine is an innovative, silk protein-based ingredient designed to provide a more sustainable, high-performance alternative to traditional petroleum-based polymers which are for […]

Read more

Commit Biologics appoints leading industry experts to newly formed Scientific Advisory Board

/in

Industry and scientific experts in molecular biology, immunology and antibody research appointed to help develop Commit’s BiCE™ technology platform to treat autoimmune disease and cancer Leading antibody expert Janine Schuurman to co-chair Commit’s Scientific Advisory Board alongside Commit’s CEO Mikkel Wandahl Pedersen Joined by Paul Parren, Gavin Thurston, Susan Kalled, and Esper Boel on the […]

Read more

Asgard Therapeutics strengthens its Board of Directors and Advisory Board with leading experts in drug development and cancer immunotherapy

/in

Highly experienced biopharma executive Dr Cristina Csimma joins Asgard’s Board of Directors, while esteemed immunologists Prof Ignacio Melero and Prof Brian Brown join Advisory Board Appointments strengthen Asgard’s team as it progresses IND-enabling studies for its lead asset AT-108 – a first-in-class, off-the-shelf cell reprogramming therapy that leads to personalized and potent anti-cancer immune responses […]

Read more

Amber Implants Announces Successful One-Year Follow-Up Data in First-in-Human Clinical of VCFix® Spinal System

/in

One-year follow-up data from first-in-human trial shows significant improvements in key clinical performance outcomes  This data supports a strong safety profile for the VCFix® Spinal System for the treatment of vertebral compression fractures The Hague, The Netherlands, 3 June 2025 – Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces […]

Read more